TVRD — Tvardi Therapeutics, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1346830 ·
Last close
$1.27
Market Cap
$16.94M
52W High
$43.65
52W Low
$0.93
ADV30
181,963
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -6,629,000 | -6,457,000 | 17,517,000 | 15,765,000 | 9,135,000 |
| Mar 2026 | 0 | — | -7,051,000 | -6,804,000 | 25,817,000 | 19,851,000 | 11,312,000 |
| Dec 2025 | 0 | — | -7,587,000 | -7,275,000 | 32,073,000 | 20,734,000 | 11,127,000 |
| Sep 2025 | 0 | — | -5,938,000 | -5,527,000 | 39,021,000 | 21,418,000 | 11,155,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-21,669,000
Investing CF
$5,775,000
Financing CF
$24,306,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-3.10
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-117,254,000
Inventory
$900,000
Receivables
$2,238,000
ST Investments
$5,130,000
EBIT TTM
$-29,445,000
Pretax Income TTM
$-15,439,000
Interest Exp TTM
$2,867,000
Analysts
8
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -26,748,000 | -18,214,000 | 32,073,000 | 11,127,000 | 20,946,000 | -23,499,000 |
| Dec 2024 | 0 | -28,107,000 | -29,397,000 | 35,199,000 | 126,330,000 | -91,131,000 | -18,305,000 |
| Dec 2023 | 0 | -18,665,000 | -17,347,000 | 27,001,000 | 89,059,000 | -62,058,000 | -21,040,000 |
| Dec 2022 | 0 | -21,193,000 | -20,542,000 | 45,097,000 | 90,148,000 | -45,051,000 | -17,866,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-2.24
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| CLRB | Cellectar Biosciences, Inc. | $17.01M | $1.80 | — |
| NCEL | NewcelX Ltd. | $17.02M | $2.95 | — |
| KTTA | Pasithea Therapeutics Corp. | $16.67M | $0.50 | — |
| LPCN | Lipocine Inc. | $17.31M | $2.10 | — |
| INTI | Inhibitor Therapeutics, Inc. | $17.48M | $0.10 | — |
News headlines (Yahoo Finance, 1h cache)
New Preclinical Data Further Support Potential for Tvardi’s STAT3 Inhibitors in Ulcerative Colitis (UC)
2026-09-24 12:00 · Yahoo
Tvardi Therapeutics Selects Ulcerative Colitis as Initial Indication for TTI-109
2026-07-30 11:30 · Yahoo
Tvardi Therapeutics to Participate in Upcoming Investor Events
2026-05-21 12:00 · Yahoo
Tvardi Therapeutics Announces First Quarter 2026 Results and Provides Business Update
2026-05-08 11:00 · Yahoo
Tvardi Therapeutics to Participate in the Raymond James Biotech Innovation Symposium
2026-04-02 12:00 · Yahoo
Tvardi Therapeutics Announces Fourth Quarter and Full-Year 2025 Results and Provides Business Update
2026-03-31 20:01 · Yahoo
Tvardi Therapeutics’ TTI-109 Phase 1 Study Confirms Prodrug Design, Improved Tolerability and Pharmacodynamic Evidence of STAT3 Target Engagement
2026-07-07 11:00 · Yahoo
Tvardi Therapeutics Announces Second Quarter 2026 Results and Provides Business Update
2026-08-14 11:00 · Yahoo
Tvardi Therapeutics to Host KOL Webinar on the Clinical Potential of TTI-109 in Ulcerative Colitis (UC) and the Evolving Treatment Landscape, on August 19, 2026
2026-08-12 12:00 · Yahoo
TVRD Stock Rallies 149% So Far This Week: Here's What You Should Know
2026-07-09 14:52 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.